Malignant Germ Cell Tumors of the Ovary: A Clinical and Pathological Study of 42 Cases.
- Author:
So Ra KIM
1
;
Jun Hee NA
;
Jong Hyeok KIM
;
Dae Joon CHUN
;
Yong Man KIM
;
Young Tak KIM
;
Joo Hyun NAM
;
Jung Eun MOK
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Malignant ovarian germ cell tumor
- MeSH:
Chungcheongnam-do;
Drug Therapy;
Dysgerminoma;
Endodermal Sinus Tumor;
Female;
Follow-Up Studies;
Germ Cells*;
Gynecology;
Humans;
Neoplasms, Germ Cell and Embryonal*;
Obstetrics;
Ovary*;
Parity;
Retrospective Studies;
Survival Rate;
Teratoma;
Ulsan
- From:Korean Journal of Gynecologic Oncology and Colposcopy
1998;9(3):289-299
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
From July, 1989 to June, 1998 forty-two patients with malignant germ cell tumors of the ovary treated in the department of Obstetrics and Gynecology, University of Ulsan, Asan Medical Center, were identified. Demographic characteristics, symptoms, signs, stage, tumor grade, mode of therapy and results of follow-up of those patients were reviewed retrospectively. The patients with malignant germ cell tumor constituted 11.1% of all ovarian malignancies and 5.6% of all ovarian germ cell tumors ecountered during this period. The most common histologic subtype was dysgerminoma (26.2%) followed by endodermal sinus tumor (23.8%) and immature teratoma (19.0%). The age of the patients ranged from 8 to 64 years (mean+/-S.D.; 26.0+/-12.9) and the mean parity was 0.8 (+/-1.6). The most frequent initial symptoms were adbominal pain (33.3%) or abdominal distension (31.0%). Most had stage I(25 cases, 59.9%) or II(6 cases, 14.3%) diseases. Elevated level of serum alpha-FP was observed in all cases of endodermal sinus tumor and embryonal cell carcinoma, CA 125 was elevated in 63.9% of all malignant germ cell tumors. Thirty-one patients (73.8%) were treated by surgery and chemotherapy and 10 patients (23.8%) by surgery only. The major chemotherapeutic regimens were BEP (bleomycin +etoposide +cisplatin) and VAC (vincristine +actinomycin-D +cytoxan). The mean follow-up duration was 24.6 (+/-23.5) months and 2-year survival rate was 88.6% (+/-0.6).
